Results from the Lung Health Study |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
ABSTRACT |
|---|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
We analyzed Lung Health Study (LHS) data to assess the effect of self-reported lower respiratory illnesses resulting in physician visits (LRI) on lung function. Participants were 5,887 smokers aged 35-60 yr, FEV1/FVC < 0.70 and FEV1 of 55-90% predicted. Two-thirds were randomized into an intensive smoking cessation program (SI); one-third were advised only to stop smoking (UC). For 5 yr participants had annual spirometry and questioning regarding LRI. SI had greater rates of smoking cessation than usual care (UC) with fewer LRI (p = 0.0008). Sustained quitters had fewer LRI than continuing smokers (p = 0.0003). In the year LRI occurred, FEV1 did not change in sustained quitters, but decreased significantly in smokers (p = 0.0001) with some recovery the following year if no LRI occurred. Over 5 yr, LRI had a significant effect on rate of decline of FEV1 only in smokers. In smokers averaging one LRI/yr over 5 yr there were additional declines in FEV1 of 7 ml /yr (p = 0.001). Smokers with more than one LRI/yr had greater declines. Chronic bronchitis was associated with increased frequencies of LRI, but did not affect their influence on lung function. Smoking and LRI had an interactive effect on FEV1 in people with mild COPD, and in smokers frequent LRI may influence the long-term course of the disease.
Keywords: smoking; chronic obstructive pulmonary disease; lower respiratory infections; chronic bronchitis
| |
INTRODUCTION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Chronic obstructive pulmonary disease (COPD) is characterized by periodic exacerbations of cough, sputum, and dyspnea, frequently due to infections of the lower respiratory tract. Studies of the effect of such episodes on the progression of COPD have been inconclusive. Fletcher and coworkers studied 792 London working men, smokers and nonsmokers, with and without airway disease and concluded that episodes of lower respiratory illness had no effect on the annual rate of change of the FEV1 (1). Similarly, Howard (2) followed British workers with and without respiratory problems for 11 yr and detected no effect of acute respiratory illness on the change in FEV1. He noted that FEV1 declines occurred prior to any documented respiratory illness. A 12-yr study of male smoking Canadian war veterans with "chronic bronchitis" also failed to demonstrate a role for respiratory infections in the progression of airways obstruction (3). On the other hand, in the United States, patients with COPD were followed for an average of 4 yr with weekly surveillance, and a more rapid FEV1 decline was associated with more frequent episodes of lower respiratory infection (4). None of these studies evaluated interactions between lower respiratory illnesses and smoking status on the annual change of lung function.
The Lung Health Study (LHS) was a 5-yr, prospective, randomized, multicenter clinical trial that followed a large number of smokers with mild COPD (5). This report presents the LHS experience regarding the frequency of respiratory illnesses and the effect of respiratory illnesses on changes in lung function, as influenced by smoking status.
| |
METHODS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Study Design
The LHS was designed to determine whether smoking intervention and regular use of a bronchodilator could slow the decline in FEV1 in persons at high risk for significant COPD (6). The LHS recruited 5,887 smokers, aged 35 to 60 yr, who were free of significant morbidity, had a baseline FEV1/FVC less than 0.70, and an FEV1 between 55 and 90% of predicted (7). Participants were randomized into three groups: (1) smoking intervention and inhaled ipratropium bromide (Atrovent) (SI-A); (2) smoking intervention and inhaled placebo (SI-P); and (3) usual care (UC), only advice to stop smoking.
Details of the study have been published previously (5). Participants underwent follow-up spirometry annually for 5 yr (6). Respiratory symptoms were recorded at baseline and annually with the ATS-DLD respiratory symptom questionnaire with minor modifications (8). Annually participants were asked about episodes of bronchitis, pneumonia, influenza, or chest colds resulting in physician visits during the previous year. These self-reported illnesses were grouped together as LRI. Chronic bronchitis was defined as cough and sputum on most days for 3 mo of the preceding year.
Participants were categorized as sustained quitters (stopped smoking for the entire 5-yr study period), intermittent smokers (smoking at one or more but not all annual visits), or continuous smokers (those that never stopped smoking).
Statistical Methods
Baseline differences between SI versus UC were evaluated using t tests for quantitative variables such as FEV1 and chi-square tests for categorical variables such as sex. LRI rates were computed using the number of self-reported visits at each annual follow-up. Adjusted rates were estimated using analysis of covariance, controlling for sex, age, educational level, baseline cigarettes /d, race (African-American versus other), baseline rates of physician visits for LRI, baseline FEV1, and O'Connor slope as a measure of airway reactivity (9).
The relationship between changes in FEV1 during follow-up and changes in illness status was examined using a mixed-effects repeated-measures analysis of covariance (10). The dependent variable was change in FEV1 expressed either as a percentage of predicted or in milliliters, from baseline to each annual visit. LRI status was entered as a time-dependent categorical variable.
Analyses looking at short-term changes in FEV1 as a function of LRI during the preceding year were carried out comparing treatment groups and smoking status categories and were adjusted for the baseline covariates noted above.
The effects of LRI frequency on the 5-yr rate of decline of FEV1 were analyzed using analyses of covariance. Separate analyses were performed for SI versus UC and by final smoking status. Analyses were controlled for age, sex, cigarettes/d, baseline FEV1 percentage predicted, percentage bronchodilator response, and airways reactivity (O'Connor slope). Long-term LRI effects on FEV1 decline were expressed as the change in annual rate of decline associated with one LRI/yr. Analyses were repeated excluding those participants reporting chronic bronchitis at baseline.
| |
RESULTS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Baseline characteristics of participants in the two treatment
groups are presented in Table 1; the two SI groups were combined, as there was no significant difference in the annual LRI
frequency between SI-A and SI-P (p = 0.149). There were
more women in the SI-A group (39.2%) than in the SI-P group
(36.0%, p = 0.037), but otherwise they were similar. The baseline characteristics of the SI (SI-A plus SI-P) and the UC
groups were similar, without significant differences (Table 1).
The SI group averaged more LRI visits to a physician in the 12 mo prior to the time of randomization, but this difference did
not reach significance (p = 0.098). Follow-up rates have been
previously reported and were very high being 
93% each year
for interviews and 88% for spirometry with the highest follow-up rates occurring in the final annual visit (5). Cross-sectional and 5-yr validated sustained smoking cessation rates for
the SI and UC groups are presented in Table 2. There were
more sustained quitters in the SI group than in the UC group at each annual visit, and in both groups the number of sustained quitters decreased with time. In addition, there were
more participants that were not smoking at each annual visit
in the SI group than in the UC group. These data have been
published previously (5).
|
|
Over the 5-yr study period, participants averaged 0.12-0.15 physician visits per year for "acute bronchitis," about 0.05 physician visits per year for both "pneumonia" and "influenza," and 0.07 visits per year for "chest colds." Participants averaged 0.24 physician visits per year for the combination of all these diagnoses (LRI). Baseline characteristics that were significantly associated with LRI during the study were female sex, LRI in the previous year, a relatively low FEV1, and the presence of respiratory symptoms, including dyspnea, wheeze, and chronic cough and sputum. The associations were not particularly strong, explaining about 10% of the variability of LRI. Previous LRI and sex accounted for 8.4% of the total variation.
Significant differences were few for each specific LRI disease category between the SI and UC groups. Where significance was reached, the SI group had fewer physician visits. The mean number of LRI in each treatment group for the entire 5-yr study period is shown in Figure 1A. Only a minority of the participants attending the annual visits reported having one or more LRI, and this proportion tended to increase as the study progressed. The UC group had significantly more LRI than the SI group (p = 0.0008). Analysis by final smoking status (Figure 1B) demonstrated similar differences. Overall, continuous smokers had significantly more LRI than sustained quitters (p = 0.0003). This was because LRI increased with time in continuous smokers but not in sustained quitters. Intermittent smokers showed intermediate LRI rates.
|
The presence or absence of chronic bronchitis ascertained at annual visits had a strong influence on LRI frequency reported at the same visits. Figure 2 shows LRI frequency in continuous smokers with and without chronic bronchitis at the five annual visits. At each visit, continuous smokers with chronic bronchitis had LRI rates that were 158-189% of those without chronic bronchitis (p < 0.001). LRI rates increased with time in continuous smokers whether or not they reported chronic bronchitis (p = 0.008). LRI rates in intermittent smokers were similar to those in continuous smokers in that they were strongly influenced by the coexistence of chronic bronchitis. In sustained quitters LRI rates were not significantly higher at annual visits in those with chronic bronchitis than in those without, but the small numbers of sustained quitters with symptoms of chronic bronchitis weakened the power of these comparisons.
|
Table 3 presents the relationship between LRI and the short-term adjusted mean change in FEV1 in sustained quitters and continuous smokers. FEV1 changes are expressed as percentages of the predicted normal value and refer to data collected during the immediate previous and current annual visit, classified according to the presence or absence of LRI. Thus NI refers to the change when there were no LRI (N) in the year prior to the year of an annual visit in which an LRI occurred (I). In continuous smokers, LRI had highly significant adverse associations with FEV1, which differed significantly according to LRI status. FEV1 changes were less in smokers with two consecutive years without LRI (NN) than in those with LRI during the year of study (NI, II). There also appeared to be some recovery from the acute loss associated with LRI in that the IN mean decline in FEV1 was less than that of the NI and II categories. Similar analyses of short-term changes in lung function in the SI and UC groups produced similar results. In both groups NN changes were smaller than II changes, and IN changes approached NN values. Differences between the SI and UC groups were less striking than those between sustained quitters and continuous smokers, but LRI related lung function loss was somewhat less in the SI group.
|
The influence of chronic bronchitis on the short-term changes in lung function shown in Table 3 was evaluated in two ways. The analysis was repeated excluding participants with chronic bronchitis at baseline, and the presence of chronic bronchitis at annual visits was entered as a covariate in the analyses of annual changes of lung function. Neither had a significant influence on the results.
The effect of LRI on the annual rate of change in FEV1 averaged over 5 yr is shown in Figure 3, which presents the mean annual rate of change of FEV1 in the three smoking categories as a function of the number of LRI. In sustained quitters the frequency of LRI had no effect on change of FEV1, whereas in intermittent and continuing smokers the frequency of LRI had adverse effects on the 5-yr averaged annual rate of decline of FEV1 (p value between sustained quitters and continuing smokers = 0.086). In both the SI and UC groups, FEV1 decline increased with more frequent LRI, and there was no significant difference between the slopes of the relationship between LRI frequency and lung function loss (data not shown). As previously reported (5), the overall rate of decline was significantly less in the SI group than in the UC group.
|
The magnitude of the effect of LRI on the 5-yr averaged annual rate of change in FEV1 is presented in Table 4. Sustained quitters had relatively little decline and this was unaffected by LRI. In both continuous and intermittent smoking categories, the estimated effect of one LRI/yr added to the 5-yr averaged annual decline in FEV1 was slightly more than 7 ml /yr, or 0.23-0.24%/yr of the predicted normal value. Neither eliminating participants with chronic bronchitis at baseline nor entering annually ascertained chronic bronchitis as a covariate in the analysis altered the data of Table 4.
|
Cumulative effects of LRI on the 5-yr averaged annual decline in FEV1 are shown in Table 5. Again no significant associations between LRI and annual FEV1 decline were noted in sustained quitters. In the two smoking categories LRI frequency was positively associated with loss of FEV1 and as LRI frequency increased it accounted for an increasingly larger fraction of the total annual loss of lung function. Smokers who had 1.5 or more LRI/yr had substantially more loss of lung function than those who had none.
|
| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
In LHS participants with mild COPD, self-reported LRI were associated with long-term adverse effects on lung function in those who continued to smoke cigarettes. Smokers with one LRI/ yr experienced an increased rate of loss of FEV1 that averaged 7 ml/ yr (0.24% of the predicted normal) over 5 yr. Stopping smoking not only reduced the frequency of LRI, but also prevented the accelerated loss of lung function associated with these events. The finding that LRI affected FEV1 decline only in smokers may explain the contradictory findings reported in other studies that analyzed current, former, and never smokers with and without airway obstruction as a single group (1).
The data on LRI were collected by questionnaire annually and relied on the participant reporting the information to us. We combined positive responses to questions regarding episodes of acute bronchitis, chest cold, flu, or pneumonia that necessitated a visit to a physician during the previous year into LRI as they are often used interchangeably, and any could represent an exacerbation of COPD. Analysis of only self- reported physician visits for bronchitis and chest colds gave similar, but less significant, results. Hospitalizations were too few to permit a separate analysis, although they probably included most episodes of true pneumonia. This approach has drawbacks, although it has been used in virtually all other studies assessing the frequency and significance of COPD exacerbations. We relied on participant recall, which can be erroneous. Underreporting probably occurred, but it is unlikely that quitters were more likely to underreport as they were more apt to be health conscious. However, it is also possible that quitters might deny illnesses, reinforcing their feelings that stopping smoking had improved their health. In addition to self-reported physician visits, we obtained self-reported information on the number of days in bed due to respiratory infections, which may have been recalled more accurately than physician visits. Analyses of days in bed gave similar results that were less significant due to fewer episodes. It was likely that participants had differing degrees of access to physicians, and restricted access would mean fewer visits irrespective of health status. Again, because of concern regarding personal health, a bias toward underreporting was probably more likely in continuing smokers than in quitters. Participants with symptoms and relatively low values of FEV1 might be more likely to see a physician and thus report LRI. However, sex and LRI during the year previous to the onset of the observation period were the best predictors of LRI and the latter was more common in SI, a bias against the finding of fewer LRI in the SI group. When possible, we adjusted our analyses for these predictors.
LRI frequency in the Lung Health Study averaged 0.24/ yr. This was lower than that noted in most other studies of COPD. Several studies report exacerbation frequencies of 1- 3 /yr (13), but evaluated patients with worse baseline lung function than LHS participants. It seems reasonable that exacerbation frequency would increase with COPD severity, and we noted that LRI were more common in participants with poorer baseline lung function. On the other hand, a Danish study of largely healthy smokers recently reported an exacerbation frequency of 0.4-0.5/yr (18). Part of the discrepancy may be due to recall, as we questioned our participants annually whereas the Danish study did this every 6 mo (18). Also, our rates may have been lower because we required an associated physician visit, whereas the Danish investigators simply asked about symptoms. A recent report of respiratory viral infections in COPD where participants were contacted every 2 wk noted that in mild COPD there were 1.8 acute respiratory illnesses/yr. In those with moderate and severe COPD this number rose to 3.0/yr. Again, however, these illnesses include those with and without a visit to a physician (19). The frequency of LRI in the present study is similar to the frequency of "chest episodes" noted by Fletcher and coworkers (1). We therefore believe that differences in LRI frequency between this and other studies are largely explicable, and not due to error.
We replicated the finding of Fletcher and coworkers (1) that people with chronic cough and sputum had considerably more "chest episodes" than people who did not. In our study, differences in LRI frequency were confined to smokers, partly because sustained quitters who continued to have cough and sputum were uncommon. Other studies have shown that smokers were more likely to have respiratory infections, including pneumonia, than nonsmokers and that quitting smoking reduced this tendency (20, 21).
Remarkably, though the presence of chronic cough and sputum increased the frequency of LRI, it apparently did not influence the effect of LRI on lung function. Excluding participants with chronic bronchitis at baseline had no effect on LRI-associated decreases in FEV1 either in the short or long term. Entering annually ascertained cough and sputum as a covariate in the analyses of the effects of LRI on lung function also did not alter the results. Thus, independent of chronic bronchitis, the data are consistent with smoking being the major determinant of the effect of LRI on lung function.
We attempted to examine the short-term effects of LRI on lung function by comparing the 1-yr change in FEV1 according to whether an LRI occurred since the previous visit. This has the sampling problem that lung function measurements were carried out at fixed annual intervals, and not immediately before and after LRI. In spite of this, continuous smokers who reported LRI during the year preceding testing showed a larger fall in FEV1 than those who did not. Continuous smokers in the IN category had changes that approached those of smokers in the NN category (Table 3). These data were consistent with LRI being associated with a decrease in lung function that was at least partially reversible. This interpretation is in agreement with studies of patients with established COPD (13, 17, 22) showing a transient decrease in lung function with exacerbations. The unique aspect of our data was that in sustained quitters LRI had no significant effect on short-term changes in lung function (Table 3). Thus, in people with mild COPD, the effects of LRI on relatively short-term lung function changes were dependent on smoking status; there was an additive effect of smoking and LRI on the 1-yr change in FEV1. We are unaware of other studies addressing this issue.
Over the 5-yr study period the data are consistent with an effect of LRI on decline in FEV1 in continuing and intermittent smokers that was not seen in sustained quitters. LRI were associated with similar degrees of 5-yr lung function decline in the SI and UC groups. However, continuing and intermittent smokers were distinct majorities in both groups and dominated intergroup analyses. When analyses compared participants by final smoking status, substantial and significant differences were observed (Figure 3). Although this kind of post hoc analysis carries risks, the simplest interpretation is that smoking and LRI had additive effects in accelerating the rate of decline of lung function in people with mild COPD. Our finding that LRI accelerated lung function decline differs from the results of most previous studies (1). This may be because we studied a large relatively homogeneous population, because of the high quality of our lung function measurements (23) and high rates of follow-up, and /or because we analyzed smokers and nonsmokers separately. Figure 3 indicates that smoking cessation favorably influenced the effect of LRI on lung function. To our knowledge this has not been previously reported.
This investigation demonstrates that LRI were associated with an accelerated loss of lung function in smokers; this may not be a cause and effect relationship. A plausible hypothesis as to how LRI might compromise lung function is that CD8+ T lymphocytes are found in increased numbers in the airways of smokers with COPD and in animals infected with respiratory syncytial virus (RSV) (24). A recent study noted normal CD8+ cell counts in ex-smoking patients with COPD (29). Blood T lymphocyte subsets in current smokers also demonstrated increased levels of CD8+ cells, but when the smokers had quit for 6 wk these levels reverted to those noted in never smokers (30). The role of the CD8+ T lymphocyte is complex (31) but in one study in RSV-infected mice the infusion into the lung of specific CD8+ T lymphocytes accelerated RSV clearance but resulted in additional lung damage (32). Thus, the combination of current smoking and a viral infection, a likely cause of LRI in our population (19), may have increased the numbers of lung CD8+ T lymphocytes. Nicotine also may act on lymphocyte receptors and affect the function of this inflammatory cell. This could result in cytokine release with recruitment of neutrophils and other cells causing further airway and/or parenchymal damage. In former smokers the background level of CD8+ T lymphocytes may have decreased and this decrease may have minimized airway damage. Also, the possible absence of nicotine affecting lymphocyte function could be important.
In smokers with airways obstruction, the effect of LRI upon lung function may not be trivial, especially in those with chronic cough and sputum. Although a single LRI/yr was associated with an increase in rate of FEV1 decline of only 7 ml/yr, multiple LRI were associated with larger losses, and the presence of chronic bronchitis increased LRI frequency. Indeed, our results may well explain the finding that smokers with chronic cough and sputum have faster declines of lung function and more morbidity than those without these symptoms (33). We also observed an increase in frequency of LRI with time in smokers. This was compatible with LRI frequency increasing as lung function is compromised, a reasonable postulate, in view of studies of more severe COPD (13). The interactive effects of smoking and LRI on lung function are therefore likely accentuated as COPD progresses. As shown in Table 5, smokers with more than one LRI/yr had substantially more rapid declines of FEV1 than those with no LRI. There are many data indicating that 1.5 or more exacerbations per year are common for patients with COPD (13).
In summary, the LHS findings demonstrate that in study participants with mild COPD stopping smoking reduced the number of reported lower respiratory illnesses that cause a visit to a physician. In addition, continuing smokers suffered both short- and long-term adverse lung function changes associated with these illnesses. In active smokers one LRI/yr resulted in a 5-yr annualized averaged acceleration in the decline of FEV1 of about 7 ml/yr (0.24% of the FEV1 as a percentage of the predicted normal value). Although the presence of chronic bronchitis did not affect the influence of LRI on FEV1, it increased the frequency of LRI and presumably their cumulative effect on lung function. Stopping smoking protected these people with mild COPD from this additional loss of lung function.
| |
Footnotes |
|---|
Correspondence should be addressed to Dr. Richard E. Kanner, University of Utah Health Sciences Center, 701 Wintrobe Bldg., Salt Lake City, UT 84132. E-mail: Kanner{at}med.utah.edu. Requests for reprints should be addressed to Dr. John E. Connett, LHS Coordinating Center, Suite 200, 2221 University Ave. SE, Minneapolis, MN 55414. E-mail: john-c{at}blueox.ccbr.umn.edu.
(Received in original form October 5, 2000 and in revised form April 19, 2001).
For a complete list of participating investigators see the APPENDIX.
Acknowledgments:
Supported by Contract No. 1 HR 46014 and NO 1 HR 46002 from the Division
of Lung Disease, National Heart, Lung, and Blood Institute.
| |
References |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
1. Fletcher C, Peto R, Tinker C, Speizer F. The natural history of chronic bronchitis and emphysema. Oxford: Oxford University Press; 1976.
2. Howard P. A long-term follow-up of respiratory symptoms and ventilatory function in a group of working men. Br J Industr Med 1970; 27: 326-333 [Medline].
3. Bates D. The fate of the chronic bronchitic: a report of the 10-year follow-up in the Canadian Department of Veteran's Affairs coordinated study of chronic bronchitis. Am Rev Respir Dis 1973; 108: 1043-1065 [Medline].
4. Kanner R, Renzetti A, Klauber M, Smith C, Golden C. Variables associated with changes in spirometry in patients with obstructive lung diseases. Am J Med 1979; 67: 44-50 [Medline].
5.
Anthonisen N,
Connett J,
Kiley J,
Altose M,
Bailey W,
Buist A,
Conway W,
Enright P,
Kanner R,
O'Hara P, et al
.
. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the
rate of decline of FEV1.
JAMA
1994;
272:
1497-1505
6. Connett J, Kusek J, Bailey W, O'Hara P, Wu M. Design of the Lung Health Study: a randomized clinical trial of early intervention for chronic obstructive pulmonary disease. Controlled Clin Trials 1993;14(2S):3-19.
7. Crapo R, Morris A, Gardner R. Reference spirometric values using techniques and equipment that meet ATS specifications. Am Rev Respir Dis 1981; 123: 659-664 [Medline].
8. Ferris BG. Epidemiology Standardization Project. Am Rev Respir Dis 1978;118(Part 2):7-35.
9. O'Connor G, Sparrow D, Taylor D, Segal M, Weiss S. Analysis of dose response curves to methacholine: an approach suitable for population studies. Am Rev Respir Dis 1987; 136: 1412-1417 [Medline].
10. Laird N, Ware J. Random effects models for longitudinal data. Biometrics 1982; 38: 963-974 [Medline].
11. Jennrich R, Schluchter M. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986; 42: 805-820 [Medline].
12. SAS I. SAS/STAT Software: Changes and Enhancements through Release 6.12. SAS Institute, Inc., Cary, NC; 1997.
13. Anthonisen N, Manfreda J, Warren C, Hershfield E, Harding G, Nelson N. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204 .
14. Paggiaro P, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773-780 [Medline].
15.
Burge PS,
Calverley PM,
Jones PW,
Spencer S,
Anderson JA,
Maslen TK.
Randomized placebo-controlled study of fluticasone propionate
in patients with moderate to severe chronic obstructive pulmonary
disease: the ISOLDE trial.
Br Med J
2000;
320:
1297-1303
16.
Collet J,
Shapiro S,
Ernst P,
Renzi P,
Ducruet T,
Robinson A.
Effects of
an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease.
Am J
Respir Crit Care Med
1997;
156:
1719-1724
17.
Seemungal T,
Donaldson G,
Paul E,
Bestall J,
Jefferies D,
Wedzicha J.
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med
1998;
157:
1418-1422
18. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999; 353: 1819-1823 [Medline].
19.
Greenberg S,
Allen M,
Wilson J,
Atmar R.
Respiratory viral infections
in adults with and without chronic obstructive pulmonary disease.
Am
J Respir Crit Care Med
2000;
162:
167-173
20. Haynes WJ, Krstulovic V, Bell AJ. Smoking habit and incidence of respiratory tract infections in a group of adolescent males. Am Rev Respir Dis 1966; 93: 730-735 [Medline].
21.
Almirall J,
Gonzalez C,
Balanzo X,
Bolibar I.
Proportion of community-acquired pneumonia cases attributable to tobacco smoking.
Chest
1999;
116:
375-379
22.
Niewoehner D,
Erbland M,
Deupree R,
Collins D,
Gross N,
Light R.
Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.
N Engl J Med
1999;
340:
1941-1947
23. Enright P, Johnson L, Connett J, Voelker H, Buist A. Spirometry in the Lung Health Study: I. Methods and quality control. Am Rev Respir Dis 1991; 143: 1215-1233 [Medline].
24. Ramsay A, Ruby J, Ramshaw I. A case for cytokines as effector molecules in the resolution of viral infection. Immunol Today 1993; 14: 155-157 [Medline].
25.
Srikiatkhachorn A,
Braciale T.
Virus-specific CD8+ T lymphocytes
downregulate T helper cell type 2 cytokine secretion and pulmonary
eosinophilia during experimental murine respiratory syncytial virus
infection.
J Exp Med
1997;
186:
421-432
26. O'Shaughnessy T, Ansari T, Barnes N, Jeffery P. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857 [Abstract].
27.
Saetta M,
DiStefano A,
Turato G,
Facchini F,
Corbino L,
Mapp C,
Maestrelli P,
Ciaccia A,
Fabri L.
CD8+ T lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease.
Am J
Respir Crit Care Med
1998;
157:
822-826
28. Costabel U, Maier K, Teschler H, Wang Y. Local immune components in chronic obstructive pulmonary disease. Respiration 1992;59(Suppl 1):17-19.
29.
Rutgers S,
Postma D,
ten Hacken N,
Kauffman H,
van der Mark T,
Koeter G,
Timens W.
Ongoing airway inflammation in patients with
COPD who do not currently smoke.
Thorax
2000;
55:
12-18
30.
Miller L,
Goldstein G,
Murphy M,
Ginns L.
Reversible alterations in immunoregulatory T cells in smoking.
Chest
1982;
82:
526-529
31.
Seder R,
LeGros G.
The functional role of CD8+ T helper type 2 cells.
J
Exp Med
1995;
181:
5-7
32.
Cannon M,
Openshaw P,
Askonas B.
Cytotoxic T cells clear virus but
augment lung pathology in mice infected with respiratory syncytial virus.
J Exp Med
1988;
168:
1163-1168
33. Vestbo J, Prescott E, Lange P, CCHS Group. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med 1996;153:1530- 1535.
34. Kanner R, Connett J, Williams D, Buist A. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: The Lung Health Study. Am J Med 1999; 106: 410-416 [Medline].
35.
Speizer F,
Fay M,
Dockery D,
Ferris BJ.
Chronic obstructive pulmonary
disease mortality in six U.S. cities.
Am Rev Respir Dis
1989;
140:
S49-S55
[Medline].
| |
APPENDIX |
|---|
The principal investigators and senior staff of the clinical and coordinating centers, the NHLBI, members of the Safety and Data Monitoring Board, and the Morbidity and Mortality Review Board are as follows:
Case Western Reserve University, Cleveland, OH
M.D. Altose, M.D. (Principal Investigator)
A.F. Conners, M.D. (Co-Principal Investigator)
S. Redline, M.D. (Co-Principal Investigator)
C.D. Deitz, Ph.D.
R.F. Rakos, Ph.D.
Henry Ford Hospital, Detroit, MI
W.A. Conway, Jr., M.D. (Principal Investigator)
A. DeHorn, Ph.D. (Co-Principal Investigator)
J.C. Ward, M.D. (former Co-Principal Investigator)
C.S. Hoppe-Ryan, C.S.W.
R.L. Jentons, M.A.
J.A. Reddick, R.N.
C. Sawicki, R.N., M.P.H.
Johns Hopkins University School of Medicine, Baltimore, MD
R.A. Wise, M.D. (Principal Investigator)
S. Permutt, M.D. (Co-Principal Investigator)
C.S. Rand, Ph.D. (Co-Principal Investigator)
Mayo Clinic, Rochester, MN
P.D. Scanlon, M.D. (Principal Investigator)
L.J. Davis, Ph.D. (Co-Principal Investigator)
R.D. Hurt, M.D. (Co-Principal Investigator)
R.D. Miller, M.D. (Co-Principal Investigator)
D.E. Williams, M.D. (Co-Principal Investigator)
G.M. Caron
G.G. Lauger, M.S.
S.M. Toogood (Pulmonary Function Quality Control Manager)
Oregon Health Sciences University, Portland, OR
A.S. Buist, M.D. (Principal Investigator)
W.M. Bjornson, M.P.H. (Co-Principal Investigator)
L.R. Johnson, Ph.D. (LHS Pulmonary Function Coordinator)
University of Alabama at Birmingham, Birmingham, AL
W.C. Bailey, M.D. (Principal Investigator)
C.M. Brooks, Ed.D. (Co-Principal Investigator)
J.J. Dolce, Ph.D.
D.M. Higgins
M.A. Johnson
B.A. Martin
University of California, Los Angeles, CA
D.P. Tashkin, M.D. (Principal Investigator)
A.H. Coulson, Ph.D. (Co-Principal Investigator)
H. Gong, M.D. (former Co-Principal Investigator)
P.I. Harber, M.D. (Co-Principal Investigator)
V.C. Li, Ph.D., M.P.H. (Co-Principal Investigator)
M.A. Nides, Ph.D.
M.S. Simmons
I.P. Zuniga
University of Manitoba, Winnipeg, Canada
N.R. Anthonisen, M.D. (Principal Investigator)
J. Manfreda, M.D. (Co-Principal Investigator)
R.P. Murray, Ph.D. (Co-Principal Investigator)
S.C. Rempel-Rossum
J.M. Stoyko
University of Minnesota Coordinating Center, Minneapolis, MN
J.E. Connett, Ph.D. (Principal Investigator)
M.O. Kjelsberg, Ph.D. (Co-Principal Investigator)
M.K. Cowles, Ph.D.
D.A. Durkin
P.L. Enright, M.D.
K.J. Kurnow, M.S.
W.W. Lee, M.S.
P.G. Lindgren, M.S.
S. Mongin, M.S.
P. O'Hara, Ph.D. (LHS Intervention Coordinator)
H.T. Voelker
L. Waller, Ph.D.
University of Pittsburgh, Pittsburgh, PA
G.R. Owens, M.D. (Principal Investigator)
R.M. Rogers, M.D. (Co-Principal Investigator)
J.J. Johnston, Ph.D.
F.P. Pope, M.S.W.
F.M. Vitale, M.A.
University of Utah, Salt Lake City, UT
R.E. Kanner, M.D. (Principal Investigator)
M.A. Rigdon, Ph.D. (Co-Principal Investigator)
K.C. Benton
P.M. Grant
The Salt Lake City Center has been assisted by the Clinical Research Center, Public Health Research Grant MO1-RR00064 from the National Center for Research Resources.
Safety and Data Monitoring Board
M. Becklake, M.D.
B. Burrows, M.D.
P. Cleary, Ph.D.
P. Kimbel, M.D. (Chairperson; deceased October 27, 1990)
L. Nett, R.N. (former member)
J.K. Ockene, Ph.D.
R.M. Senior, M.D. (Chairperson)
G.L. Snider, M.D.
W. Spitzer, M.D. (former member)
O.D. Williams, Ph.D.
National Heart, Lung, and Blood Institute Staff, Bethesda, MD
S.S. Hurd, Ph.D. (Director, Division of Lung Diseases)
J.P. Kiley, Ph.D. (Project Officer)
M.C. Wu, Ph.D. (Division of Epidemiology & Clinical Applications)
Mortality and Morbidity Review Board
S.M. Ayres, M.D.
R.E. Hyatt, M.D.
B.A. Mason, M.D.
This article has been cited by other articles:
 |
|
 |
|
  N. N. Hansel, L. Gao, N. M. Rafaels, R. A. Mathias, E. R. Neptune, C. Tankersley, A. V. Grant, J. Connett, T. H. Beaty, R. A. Wise, et al. Leptin receptor polymorphisms and lung function decline in COPD Eur. Respir. J., July 1, 2009; 34(1): 103 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-R. Burgel, P. Nesme-Meyer, P. Chanez, D. Caillaud, P. Carre, T. Perez, N. Roche, and on behalf of the Initiatives Bronchopneumopathie C Cough and Sputum Production Are Associated With Frequent Exacerbations and Hospitalizations in COPD Subjects Chest, April 1, 2009; 135(4): 975 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Hurst, G. C. Donaldson, J. K. Quint, J. J. P. Goldring, R. Baghai-Ravary, and J. A. Wedzicha Temporal Clustering of Exacerbations in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., March 1, 2009; 179(5): 369 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P N Black and C F McDonald Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease Postgrad. Med. J., March 1, 2009; 85(1001): 141 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Roede, P. Bresser, J. M. Prins, F. Schellevis, T. J. M. Verheij, and P. J. E. Bindels Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD Eur. Respir. J., February 1, 2009; 33(2): 282 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Braman Chronic Obstructive Pulmonary Disease ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 153 - 186. [Full Text] [PDF]
|
|
|
|
|
|
T. A. R. Seemungal, T. M. A. Wilkinson, J. R. Hurst, W. R. Perera, R. J. Sapsford, and J. A. Wedzicha Long-term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive Pulmonary Disease Exacerbations Am. J. Respir. Crit. Care Med., December 1, 2008; 178(11): 1139 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Godtfredsen, T. H. Lam, T. T. Hansel, M. E. Leon, N. Gray, C. Dresler, D. M. Burns, E. Prescott, and J. Vestbo COPD-related morbidity and mortality after smoking cessation: status of the evidence Eur. Respir. J., October 1, 2008; 32(4): 844 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Celli, N. E. Thomas, J. A. Anderson, G. T. Ferguson, C. R. Jenkins, P. W. Jones, J. Vestbo, K. Knobil, J. C. Yates, and P. M. A. Calverley Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH Study Am. J. Respir. Crit. Care Med., August 15, 2008; 178(4): 332 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. N. Keene, P. M. A. Calverley, P. W. Jones, J. Vestbo, and J. A. Anderson Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited Eur. Respir. J., July 1, 2008; 32(1): 17 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Quint, R. Baghai-Ravary, G. C. Donaldson, and J. A. Wedzicha Relationship between depression and exacerbations in COPD Eur. Respir. J., July 1, 2008; 32(1): 53 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Benfield, P. Lange, and J. Vestbo COPD Stage and Risk of Hospitalization for Infectious Disease Chest, July 1, 2008; 134(1): 46 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Patel, M. DeCamp, and G. J. Criner Lung Transplantation and Lung Volume Reduction Surgery versus Transplantation in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 447 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. A. Minai, J. Benditt, and F. J. Martinez Natural History of Emphysema Proceedings of the ATS, May 1, 2008; 5(4): 468 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sethi, C. Wrona, K. Eschberger, P. Lobbins, X. Cai, and T. F. Murphy Inflammatory Profile of New Bacterial Strain Exacerbations of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 491 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Groenewegen, D. S. Postma, W. C. J. Hop, P. L. M. L. Wielders, N. J. J. Schlosser, E. F. M. Wouters, and for the COSMIC Study Group Increased Systemic Inflammation Is a Risk Factor for COPD Exacerbations* Chest, February 1, 2008; 133(2): 350 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Snoeck-Stroband, T. S. Lapperre, M. M. E. Gosman, H. M. Boezen, W. Timens, N. H. T. ten Hacken, J. K. Sont, P. J. Sterk, P. S. Hiemstra, and the Groningen Leiden Universities Corticosteroids Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies Eur. Respir. J., January 1, 2008; 31(1): 70 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Silverman Exacerbations in Chronic Obstructive Pulmonary Disease: Do They Contribute to Disease Progression? Proceedings of the ATS, December 1, 2007; 4(8): 586 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Abusriwil and R. A. Stockley The Interaction of Host and Pathogen Factors in Chronic Obstructive Pulmonary Disease Exacerbations and Their Role in Tissue Damage Proceedings of the ATS, December 1, 2007; 4(8): 611 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Martinez Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, December 1, 2007; 4(8): 647 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P M A Calverley and J A Wedzicha Chronic obstructive pulmonary disease past, present and future Thorax, December 1, 2007; 62(12): 1026 - 1027. [Full Text] [PDF]
|
|
|
|
|
|
J. Bourbeau, G. Ford, H. Zackon, N. Pinsky, J. Lee, and G. Ruberto Impact on patients' health status following early identification of a COPD exacerbation Eur. Respir. J., November 1, 2007; 30(5): 907 - 913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Miravitlles Review: Do we need new antibiotics for treating exacerbations of COPD? Therapeutic Advances in Respiratory Disease, October 1, 2007; 1(1): 61 - 76. [Abstract] [PDF]
|
|
|
|
|
|
I. I. Siempos, G. Dimopoulos, I. P. Korbila, K. Manta, and M. E. Falagas Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis Eur. Respir. J., June 1, 2007; 29(6): 1127 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tsoumakidou, W. Elston, J. Zhu, Z. Wang, E. Gamble, N. M. Siafakas, N. C. Barnes, and P. K. Jeffery Cigarette Smoking Alters Bronchial Mucosal Immunity in Asthma Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 919 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Stolz, M. Christ-Crain, N. G. Morgenthaler, J. Leuppi, D. Miedinger, R. Bingisser, C. Muller, J. Struck, B. Muller, and M. Tamm Copeptin, C-Reactive Protein, and Procalcitonin as Prognostic Biomarkers in Acute Exacerbation of COPD Chest, April 1, 2007; 131(4): 1058 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Cote, L. J. Dordelly, and B. R. Celli Impact of COPD Exacerbations on Patient-Centered Outcomes Chest, March 1, 2007; 131(3): 696 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. R. Perera, J. R. Hurst, T. M. A. Wilkinson, R. J. Sapsford, H. Mullerova, G. C. Donaldson, and J. A. Wedzicha Inflammatory changes, recovery and recurrence at COPD exacerbation Eur. Respir. J., March 1, 2007; 29(3): 527 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kardos, M. Wencker, T. Glaab, and C. Vogelmeier Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on Exacerbations in Severe Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., January 15, 2007; 175(2): 144 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Niewoehner, Y. Lokhnygina, K. Rice, W. G. Kuschner, A. Sharafkhaneh, G. A. Sarosi, P. Krumpe, K. Pieper, and S. Kesten Risk Indexes for Exacerbations and Hospitalizations Due to COPD Chest, January 1, 2007; 131(1): 20 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Roghanian, E. M. Drost, W. MacNee, S. E. M. Howie, and J.-M. Sallenave Inflammatory Lung Secretions Inhibit Dendritic Cell Maturation and Function via Neutrophil Elastase Am. J. Respir. Crit. Care Med., December 1, 2006; 174(11): 1189 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E. Rascon-Aguilar, M. Pamer, P. Wludyka, J. Cury, D. Coultas, L. R. Lambiase, N. S. Nahman, and K. J. Vega Role of Gastroesophageal Reflux Symptoms in Exacerbations of COPD. Chest, October 1, 2006; 130(4): 1096 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Fernaays, A. J. Lesse, S. Sethi, X. Cai, and T. F. Murphy Differential Genome Contents of Nontypeable Haemophilus influenzae Strains from Adults with Chronic Obstructive Pulmonary Disease. Infect. Immun., June 1, 2006; 74(6): 3366 - 3374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Papi, F. Luppi, F. Franco, and L. M. Fabbri Pathophysiology of Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2006; 3(3): 245 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Wilson, P Jones, T Schaberg, P Arvis, I Duprat-Lomon, P P Sagnier, and for the MOSAIC Study Group Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis Thorax, April 1, 2006; 61(4): 337 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Dusser, M-L. Bravo, P. Iacono, and on behalf the MISTRAL study group The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J., March 1, 2006; 27(3): 547 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G C Donaldson and J A Wedzicha COPD exacerbations {middle dot} 1: Epidemiology Thorax, February 1, 2006; 61(2): 164 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Vestbo and J C Hogg Convergence of the epidemiology and pathology of COPD Thorax, January 1, 2006; 61(1): 86 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Braman Chronic Cough Due to Chronic Bronchitis: ACCP Evidence-Based Clinical Practice Guidelines Chest, January 1, 2006; 129(1_suppl): 104S - 115S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Stevenson, P. P. Walker, R. W. Costello, and P. M. A. Calverley Lung Mechanics and Dyspnea during Exacerbations of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1510 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Toews Impact of bacterial infections on airway diseases Eur. Respir. Rev., December 1, 2005; 14(95): 62 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Soler Modulation of airway inflammation to prevent exacerbations of COPD Eur. Respir. Rev., December 1, 2005; 14(95): 78 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J A Wedzicha and T A R Seemungal Inhaled corticosteroids in COPD: a light at the end of the tunnel? Thorax, December 1, 2005; 60(12): 977 - 978. [Full Text] [PDF]
|
|
|
|
|
|
P. W. Ind COPD disease progression and airway inflammation: uncoupled by smoking cessation Eur. Respir. J., November 1, 2005; 26(5): 764 - 766. [Full Text] [PDF]
|
|
|
|
|
|
P. Mallia and S. L. Johnston Mechanisms and Experimental Models of Chronic Obstructive Pulmonary Disease Exacerbations Proceedings of the ATS, November 1, 2005; 2(4): 361 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J J Soler-Cataluna, M A Martinez-Garcia, P Roman Sanchez, E Salcedo, M Navarro, and R Ochando Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax, November 1, 2005; 60(11): 925 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Donaldson, T. A. R. Seemungal, I. S. Patel, A. Bhowmik, T. M. A. Wilkinson, J. R. Hurst, P. K. MacCallum, and J. A. Wedzicha Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD Chest, October 1, 2005; 128(4): 1995 - 2004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Niewoehner, K. Rice, C. Cote, D. Paulson, J. A. D. Cooper Jr., L. Korducki, C. Cassino, and S. Kesten Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator: A Randomized Trial Ann Intern Med, September 6, 2005; 143(5): 317 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Calverley, R. Pauwels{dagger}, C-G. Lofdahl, K. Svensson, T. Higenbottam, L-G. Carlsson, and E. Stahl Relationship between respiratory symptoms and medical treatment in exacerbations of COPD Eur. Respir. J., September 1, 2005; 26(3): 406 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Vincken Bronchodilator treatment of stable COPD: long-acting anticholinergics Eur. Respir. Rev., September 1, 2005; 14(94): 23 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wilson Treatment of COPD exacerbations: antibiotics Eur. Respir. Rev., September 1, 2005; 14(94): 32 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hoogendoorn, M. P. M. H. Rutten-van Molken, R. T. Hoogenveen, M. L. L. van Genugten, A. S. Buist, E. F. M. Wouters, and T. L. Feenstra A dynamic population model of disease progression in COPD Eur. Respir. J., August 1, 2005; 26(2): 223 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Needham and R. A. Stockley Exacerbations in {alpha}1-antitrypsin deficiency Eur. Respir. J., June 1, 2005; 25(6): 992 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004 Thorax, April 1, 2005; 60(4): 343 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Donaldson, T. M. A. Wilkinson, J. R. Hurst, W. R. Perera, and J. A. Wedzicha Exacerbations and Time Spent Outdoors in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., March 1, 2005; 171(5): 446 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J R Hurst and J A Wedzicha Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation Postgrad. Med. J., September 1, 2004; 80(947): 497 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Vestbo Chronic bronchitis: should it worry us? Chronic Respiratory Disease, July 1, 2004; 1(3): 173 - 176. [Abstract] [PDF]
|
|
|
|
|
|
P. Paggiaro Does Early Treatment of Exacerbation Improve Outcome in Chronic Obstructive Pulmonary Disease? Am. J. Respir. Crit. Care Med., June 15, 2004; 169(12): 1267 - 1268. [Full Text] [PDF]
|
|
|
|
|
|
T. M. A. Wilkinson, G. C. Donaldson, J. R. Hurst, T. A. R. Seemungal, and J. A. Wedzicha Early Therapy Improves Outcomes of Exacerbations of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., June 15, 2004; 169(12): 1298 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.R. Anthonisen The British hypothesis revisited Eur. Respir. J., May 1, 2004; 23(5): 657 - 658. [Full Text] [PDF]
|
|
|
|
|
|
S. Spencer, P.M.A. Calverley, P.S. Burge, and P.W. Jones Impact of preventing exacerbations on deterioration of health status in COPD Eur. Respir. J., May 1, 2004; 23(5): 698 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Waterer and S. E. Temple Do We Really Want To Know Why Only Some Smokers Get COPD? Chest, May 1, 2004; 125(5): 1599 - 1600. [Full Text] [PDF]
|
|
|
|
|
|
M Miravitlles, M Ferrer, A Pont, R Zalacain, J L Alvarez-Sala, F Masa, H Verea, C Murio, F Ros, and R Vidal Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study Thorax, May 1, 2004; 59(5): 387 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Pauwels Similarities and Differences in Asthma and Chronic Obstructive Pulmonary Disease Exacerbations Proceedings of the ATS, April 1, 2004; 1(2): 73 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Rennard and S. G. Farmer Exacerbations and Progression of Disease in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2004; 1(2): 88 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sethi Bacteria in Exacerbations of Chronic Obstructive Pulmonary Disease: Phenomenon or Epiphenomenon? Proceedings of the ATS, April 1, 2004; 1(2): 109 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Wedzicha Role of Viruses in Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2004; 1(2): 115 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Anthonisen Lessons from the Lung Health Study Proceedings of the ATS, April 1, 2004; 1(2): 143 - 145. [Full Text] [PDF]
|
|
|
|
|
|
G.C. Donaldson, T.A.R. Seemungal, I.S. Patel, S.J. Lloyd-Owen, T.M.A. Wilkinson, and J.A. Wedzicha Longitudinal changes in the nature, severity and frequency of COPD exacerbations Eur. Respir. J., December 1, 2003; 22(6): 931 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.J. Barnes, S.D. Shapiro, and R.A. Pauwels Chronic obstructive pulmonary disease: molecular and cellularmechanisms Eur. Respir. J., October 1, 2003; 22(4): 672 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A J White, S Gompertz, D L Bayley, S L Hill, C O'Brien, I Unsal, and R A Stockley Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis Thorax, August 1, 2003; 58(8): 680 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Chien, P. J. Martin, T. A. Gooley, M. E. Flowers, S. R. Heckbert, W. G. Nichols, and J. G. Clark Airflow Obstruction after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Am. J. Respir. Crit. Care Med., July 15, 2003; 168(2): 208 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Burge and J.A. Wedzicha COPD exacerbations: definitions and classifications Eur. Respir. J., June 1, 2003; 21(41_suppl): 46S - 53s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. A. Wilkinson, I. S. Patel, M. Wilks, G. C. Donaldson, and J. A. Wedzicha Airway Bacterial Load and FEV1 Decline in Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., April 15, 2003; 167(8): 1090 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W A Biernacki, S A Kharitonov, and P J Barnes Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD Thorax, April 1, 2003; 58(4): 294 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A J White, S Gompertz, and R A Stockley Chronic obstructive pulmonary disease * 6: The aetiology of exacerbations of chronic obstructive pulmonary disease Thorax, January 1, 2003; 58(1): 73 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Tobin Compliance (COMmunicate PLease wIth Less Abbreviations, Noun Clusters, and Exclusiveness) Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): 1534 - 1536. [Full Text] [PDF]
|
|
|
|
|
|
T A R Seemungal, J A Wedzicha, P K MacCallum, S L Johnston, P A Lambert, F Blasi, L Allegra, S Damato, R Raccanelli, R Cosentini, et al. Chlamydia pneumoniae and COPD exacerbation Thorax, December 1, 2002; 57(12): 1087 - 1089. [Full Text] [PDF]
|
|
|
|
|
|
G.J. Huchon, A. Vergnenegre, F. Neukirch, G. Brami, N. Roche, and P-M. Preux Chronic bronchitis among French adults: high prevalence and underdiagnosis Eur. Respir. J., October 1, 2002; 20(4): 806 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G C Donaldson, T A R Seemungal, A Bhowmik, and J A Wedzicha Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease Thorax, October 1, 2002; 57(10): 847 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Anthonisen Bacteria and Exacerbations of Chronic Obstructive Pulmonary Disease N. Engl. J. Med., August 15, 2002; 347(7): 526 - 527. [Full Text] [PDF]
|
|
|
|
|
|
M. Miravitlles Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur. Respir. J., July 1, 2002; 20(36_suppl): 9S - 19s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Stoller Acute Exacerbations of Chronic Obstructive Pulmonary Disease N. Engl. J. Med., March 28, 2002; 346(13): 988 - 994. [Full Text] [PDF]
|
|
|
|
|
|
M. J. TOBIN Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2001 Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 642 - 662. [Full Text] [PDF]
|
|
|
|
|
|
H. E. Fessler Fallingwater and Emphysema Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1753 - 1754. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Cell Mol. Biol. |